Cardiol Therapeutics (CRDL) Change in Account Payables (2020 - 2026)

Cardiol Therapeutics has reported Change in Account Payables for 7 years, with the latest figure at $2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables rose 383.7% year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2026 stood at $2.5 million (up 385.67% YoY), and the FY2025 full-year result was $2.5 million, up 427.29% from the prior year.
• Change in Account Payables for Q1 2026 stood at $2.5 million, up from $193629.1 in the prior quarter.
• The five-year high for Change in Account Payables was $5.8 million in Q2 2025, with the low at -$2.3 million in Q3 2024.
• Historically, Change in Account Payables has averaged $765867.9 across 5 years, with a median of $515505.6 in 2025.
• Annual changes were most pronounced in 2024 — Change in Account Payables slumped 13493.07% — and 2025, when it jumped 1263.44%.
• Cardiol Therapeutics' Change in Account Payables stood at $1.2 million in 2022, then tumbled by 49.56% to $624557.2 in 2023, then dropped by 21.85% to $488094.6 in 2024, then sank by 60.33% to $193629.1 in 2025, then surged by 1187.78% to $2.5 million in 2026.
• The last three Change in Account Payables figures came in at $2.5 million (Q1 2026), $193629.1 (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.